Published in AIDS Weekly, December 25th, 2000
The results were described at the Collaborative Research Seminar on HIV Entry and Fusion Inhibitors. HIV entry inhibitors are viewed as a promising category of anti-HIV drugs which may offer significant benefits in both safety and efficacy versus currently available HIV therapies.
The development programs for PRO 542 and PRO 140 were described in an invited talk delivered by William C. Olson, PhD, Progenics. Included in the presentation were new findings on the sequence of molecular events that enable PRO 542, PRO...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.